Skip to main content
OpenTrials
Completed

NCT Number: NCT02891109

Regulatory B Cells and Chronic Immune Thrombocytopenia

The chronic immune thrombopenia is an autoimmune disease caused by B cells. These cells produce anti platelets and megakaryocytes antibodies. Some B cells, named regulatory B cells, are known to control other cells. Their action in chronic immune thrombopenia is actually unknown.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Purpura, Thrombocytopenic, Idiopathic Autoimmune Diseases Blood Coagulation Disorders Blood Platelet Disorders Cytopenia Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhage Hemorrhagic Disorders Immune System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Purpura Purpura, Thrombocytopenic Regulatory B Cells Signs and Symptoms Skin Manifestations Thrombocytopenia Thrombotic Microangiopathies

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU de Brest

Brest, 29609, France

About this study

The chronic immune thrombopenia is an autoimmune disease caused by B cells. These cells produce anti platelets and megakaryocytes antibodies. Some B cells, named regulatory B cells, are known to control other cells. Their action in chronic immune thrombopenia is actually unknown. In our cohort of chronic immune thrombopenia and controls, we realized a flow cytometry analyze of B and T cells and a co-culture to determine regulatory B cells functionality.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Purpura, Thrombocytopenic, Idiopathic, chronic phase (>12 months)
  • no treatment or thrombopoietin receptor agonists

Exclusion criteria

  • < 18 years
  • Purpura, Thrombocytopenic, Idiopathic, acute phase
  • pregnancy
  • others causes of thrombopenia

Treatment and study plan

Biological tests

Biological

From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry

Primary outcomes

  1. Regulatory B cells functionality

    Time frame: 1 week

    inhibition of T cells proliferation with co-culture B and T cells

Secondary outcomes

  1. Cytometry immunophenotyping of B and T cells

    Time frame: 1 week

    characterization of B and T cells by flow cytometry

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Official study title

The Role of Regulatory B Cells in the Chronic Immune Thrombocytopenia

Acronym: PTIREG

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Sep 7, 2016
Registry last updated
Sep 7, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.